- Home
- PHAT vs RM Comparison
PHAT vs RM Comparison
Compare PHAT & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- RM
- Stock Information
- Founded
- PHAT 2018
- RM 1987
- Country
- PHAT United States
- RM United States
- Employees
- PHAT N/A
- RM N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- RM Finance: Consumer Services
- Sector
- PHAT Health Care
- RM Finance
- Exchange
- PHAT Nasdaq
- RM Nasdaq
- Market Cap
- PHAT 289.0M
- RM 282.1M
- IPO Year
- PHAT 2019
- RM 2012
- Fundamental
- Price
- PHAT $8.92
- RM $27.50
- Analyst Decision
- PHAT Strong Buy
- RM Hold
- Analyst Count
- PHAT 4
- RM 3
- Target Price
- PHAT $16.25
- RM $30.00
- AVG Volume (30 Days)
- PHAT 4.4M
- RM 42.3K
- Earning Date
- PHAT 05-01-2025
- RM 07-30-2025
- Dividend Yield
- PHAT N/A
- RM 4.37%
- EPS Growth
- PHAT N/A
- RM 41.13
- EPS
- PHAT N/A
- RM 3.29
- Revenue
- PHAT $81,859,000.00
- RM $577,647,000.00
- Revenue This Year
- PHAT $195.45
- RM $13.10
- Revenue Next Year
- PHAT $106.76
- RM $9.35
- P/E Ratio
- PHAT N/A
- RM $8.33
- Revenue Growth
- PHAT 3055.70
- RM 6.45
- 52 Week Low
- PHAT $2.21
- RM $25.41
- 52 Week High
- PHAT $19.71
- RM $37.52
- Technical
- Relative Strength Index (RSI)
- PHAT 82.93
- RM 45.56
- Support Level
- PHAT $4.47
- RM $26.06
- Resistance Level
- PHAT $4.99
- RM $27.01
- Average True Range (ATR)
- PHAT 0.89
- RM 0.72
- MACD
- PHAT 0.39
- RM 0.11
- Stochastic Oscillator
- PHAT 60.60
- RM 48.06
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.